Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Share This Webinar
About This Webinar
Oxford Biomedica is delivering life changing gene therapies to patients. Our LentiVector platform is broadly accepted by big Pharma and biotech partners for efficient, permanent and cost effective delivery of genes to cells. With over 550 employees and >200,000 sqft facilities in the UK, we have the end-to-end capabilities in discovery, development, clinical and commercial GMP manufacturing of viral vectors to accelerate and derisk development of cell and gene therapies
Language:
English
Who can attend? Everyone
Featured Presenters
VP, Business Development Product Licensing
Jezz Harrop is VP of Product Licensing, Business Development, with responsibility for inlicensing and outlicensing gene therapy products
Director, Process R&D
Director within the Process Research and Development department with a primary focus on process innovation
Hosted By
The full session archive, available exclusively for attendees of the American Society of Gene & Cell Therapy's 23rd Annual Meeting, May 12-15, 2020.